title: The MDM2 309T>G polymorphism and ovarian cancer risk: a meta-analysis of 1534 cases and 2211 controls.
abstract: BACKGROUND
  Recently, there have been a number of studies on the association between MDM2 (Murine Double Minute 2) 309 polymorphism and ovarian cancer risk. However, the results of previous reports remain controversial and ambiguous. Thus, we performed a meta-analysis to explore more precisely the association between MDM2 309 polymorphism and the risk of ovarian cancer.
  
  
  METHODS
  A meta-analysis was performed to examine the association between MDM2 309T>G polymorphism and ovarian cancer risk. Odds ratio (OR) and its 95% confidence interval (CI) were used for statistical analysis.
  
  
  RESULTS
  Our publication search identified a total of 6 studies with 1534 cases and 2211 controls. No significant association was found between MDM2 309T>G polymorphism and ovarian cancer risk in total population analysis. In the subgroup meta-analysis by ethnicity, a negative association was shown in Asian subgroup (G vs. T OR = 0.774, 95% CI = 0.628-0.955, P = 0.017, P(het) = 0.327; GG vs. TT: OR = 0.601, 95% CI = 0.395-0.914, P = 0.017, P(het) = 0.417; dominant model TG+GG vs. TT: OR = 0.661, 95% CI = 0.468-0.934, P = 0.019, P(het) = 0.880), and no significant association in any genetic models among Caucasians was observed.
  
  
  CONCLUSIONS
  This meta-analysis provides evidence for the association between MDM2 309 polymorphism and ovarian cancer risk, supporting the hypothesis that MDM2 SNP309 G allele acts as an important ovarian cancer protective factor in Asians but not in Caucasians.
authors: Key Laboratory of Gastroenterology of Zhejiang Province, Zhejiang Provincial People's Hospital, Hangzhou, China.
authors: Ying-Yu
authors: YY
authors: Ma
authors: Tian-Pei
authors: TP
authors: Guan
authors: Hai-Bo
authors: HB
authors: Yao
authors: Sheng
authors: S
authors: Yu
authors: Le-Gao
authors: LG
authors: Chen
authors: Ying-Jie
authors: YJ
authors: Xia
authors: Xu-Jun
authors: XJ
authors: He
authors: Hui-Ju
authors: HJ
authors: Wang
authors: Xiao-Ting
authors: XT
authors: Jiang
authors: Hou-Quan
authors: HQ
authors: Tao
mesh_terms: D016022:Case-Control Studies; D005260:Female; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D006801:Humans; D010051:Ovarian Neoplasms / Q000201:enzymology* / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D051736:Proto-Oncogene Proteins c-mdm2 / Q000235:genetics*
chemical_list: D051736:Proto-Oncogene Proteins c-mdm2
references: Proc Natl Acad Sci U S A. 2009 Jun 23;106(25):10236-41
references: 19497887
references: Gynecol Oncol. 2003 Oct;91(1):123-9
references: 14529671
references: Oncology. 2008;74(1-2):84-7
references: 18547962
references: Cancer Cell. 2011 Feb 15;19(2):273-82
references: 21316605
references: Breast Cancer Res Treat. 2008 Oct;111(3):497-504
references: 18026875
references: Cancer Res. 2006 May 15;66(10):5104-10
references: 16707433
references: Cell. 1994 Mar 25;76(6):1013-23
references: 8137420
references: Int J Gynecol Cancer. 2009 May;19(4):572-7
references: 19509552
references: Arch Med Res. 2011 Feb;42(2):149-55
references: 21565629
references: Asian Pac J Cancer Prev. 2011;12(8):1899-903
references: 22292622
references: Cancer Res. 2005 Jul 1;65(13):5481-4
references: 15994915
references: Cell. 2004 Nov 24;119(5):591-602
references: 15550242
references: Breast Cancer Res Treat. 2010 Feb;120(1):211-6
references: 19590949
references: BMC Cancer. 2006 Mar 24;6:80
references: 16563154
references: Genes Chromosomes Cancer. 2007 Mar;46(3):239-47
references: 17171684
references: FEBS Lett. 1997 Dec 22;420(1):25-7
references: 9450543
references: Clin Cancer Res. 2007 May 1;13(9):2627-33
references: 17473193
references: Clin Cancer Res. 2008 Jan 1;14(1):89-96
references: 18172257
references: J Med Genet. 2006 Dec;43(12):950-2
references: 16825430
references: Oncogene. 2007 Feb 26;26(9):1317-23
references: 17322917
references: Carcinogenesis. 2007 Nov;28(11):2262-7
references: 17827408
references: BMC Cancer. 2011 May 29;11:208
references: 21619694
references: Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2717-23
references: 18086778
references: Nature. 1997 May 15;387(6630):299-303
references: 9153396
references: Hum Mutat. 2006 Jan;27(1):110-7
references: 16287156
references: Cancer Res. 2005 Oct 15;65(20):9582-7
references: 16230424
references: Eur J Cancer. 2012 Sep;48(13):1988-96
references: 22119201
references: Cancer Lett. 2006 Aug 28;240(2):195-7
references: 16239061
references: Oncotarget. 2011 Mar;2(3):251-8
references: 21436469
references: Nature. 1997 May 15;387(6630):296-9
references: 9153395
references: J Oncol. 2010;2010:297671
references: 20111735
references: Exp Cell Res. 2001 Mar 10;264(1):56-66
references: 11237523
references: Hum Cell. 2011 Jun;24(2):57-64
references: 21547352
references: Hum Cell. 2009 May;22(2):49-54
references: 19379464